(Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|
Turnover | 112.55%51.89M | 145.02%25.88M | 495.16%67.2M | --24.41M | 981.27%10.56M | 391.13%11.29M | --977K | --2.3M |
Operating income | 112.55%51.89M | 145.02%25.88M | 495.16%67.2M | 24.41M | 981.27%10.56M | 391.13%11.29M | 977K | 2.3M |
Cost of sales | -122.33%-27.37M | -182.83%-14.07M | -339.53%-35.14M | ---12.31M | -1,054.29%-4.98M | -703.42%-7.99M | ---431K | ---995K |
Operating expenses | -122.33%-27.37M | -182.83%-14.07M | -339.53%-35.14M | -12.31M | -1,054.29%-4.98M | -703.42%-7.99M | -431K | -995K |
Gross profit | 102.59%24.52M | 111.36%11.81M | 872.52%32.06M | 12.1M | 923.63%5.59M | 152.84%3.3M | 546K | 1.3M |
Selling expenses | -49.06%-25.38M | -186.36%-12.28M | -221.92%-38.4M | ---17.02M | -83.96%-4.29M | -10.31%-11.93M | ---2.33M | ---10.81M |
Administrative expenses | -87.00%-28.14M | -73.24%-13.99M | -95.94%-54.4M | ---15.05M | -53.92%-8.08M | -3.66%-27.76M | ---5.25M | ---26.78M |
Research and development expenses | -86.88%-64.23M | -100.52%-29.58M | -34.17%-90.73M | ---34.37M | 17.33%-14.75M | -106.43%-67.63M | ---17.84M | ---32.76M |
Revaluation surplus | 99.85%-243K | 102.11%1.51M | 57.19%-165.22M | ---163.54M | 79.98%-71.68M | 38.14%-385.89M | ---358M | ---623.76M |
-Changes in the fair value of other assets | 99.85%-243K | 102.11%1.51M | 57.19%-165.22M | ---163.54M | 79.98%-71.68M | 38.14%-385.89M | ---358M | ---623.76M |
Impairment and provision | -1,570.16%-4.14M | -800.00%-999K | -1,596.00%-848K | ---248K | -2,120.00%-111K | -284.62%-50K | ---5K | ---13K |
-Other impairment is provision | -1,570.16%-4.14M | -800.00%-999K | -1,596.00%-848K | ---248K | -2,120.00%-111K | -284.62%-50K | ---5K | ---13K |
Special items of operating profit | 9.31%-5.88M | -26.59%2.07M | -418.10%-21.37M | ---6.48M | 115.23%2.81M | 386.46%6.72M | --1.31M | --1.38M |
Operating profit | 53.93%-103.49M | 54.19%-41.46M | 29.87%-338.9M | -224.61M | 76.28%-90.51M | 30.11%-483.24M | -381.57M | -691.45M |
Financing cost | -9.46%-10.9M | -10.18%-5.46M | -5.17%-20.22M | ---9.96M | -4.91%-4.95M | -200.78%-19.22M | ---4.72M | ---6.39M |
Adjustment items of earning before tax | ---- | ---4.69M | ---- | ---- | ---- | ---- | ---- | ---- |
Earning before tax | 51.23%-114.39M | 45.94%-51.61M | 28.53%-359.12M | -234.57M | 75.29%-95.46M | 28.00%-502.46M | -386.29M | -697.84M |
After-tax profit from continuing operations | 51.23%-114.39M | 45.94%-51.61M | 28.53%-359.12M | -234.57M | 75.29%-95.46M | 28.00%-502.46M | -386.29M | -697.84M |
Earning after tax | 51.23%-114.39M | 45.94%-51.61M | 28.53%-359.12M | -234.57M | 75.29%-95.46M | 28.00%-502.46M | -386.29M | -697.84M |
Minority profit | -325.93%-61K | -2,950.00%-61K | -266.67%-33K | --27K | ---2K | -800.00%-9K | ---- | ---1K |
Profit attributable to shareholders | 51.27%-114.33M | 46.00%-51.55M | 28.53%-359.08M | -234.6M | 75.29%-95.46M | 28.00%-502.45M | -386.29M | -697.84M |
Basic earnings per share | 82.89%-0.13 | 81.25%-0.06 | 65.36%-0.62 | -0.76 | -0.32 | 61.42%-1.79 | -4.64 | |
Diluted earnings per share | 82.89%-0.13 | 81.25%-0.06 | 65.36%-0.62 | -0.76 | -0.32 | 61.42%-1.79 | -4.64 | |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data